Biotechnology
Basecamp Research Secures $60M to Revolutionize AI Drug Discovery with Broad Institute Partnership
AI drug discovery, Basecamp Research, Broad Institute, David R. Liu, Biotechnology, Gene therapy, Artificial intelligence in biology
Eli Lilly and insitro Collaborate on AI-Driven Metabolic Disease Therapies
Eli Lilly, insitro, AI, metabolic diseases, siRNA, GalNAc, drug discovery, biotechnology, pharmaceutical partnership
BIOSECURE Act: A Potential Game-Changer for Biopharma – Industry Implications and Future Directions
BIOSECURE Act, Biopharma industry, US-China relations, Biotechnology collaborations, Supply chain diversification, Regulatory compliance
BIOSECURE Act: Navigating Industry Implications and Future Directions
BIOSECURE Act, Biotechnology industry, Supply chain disruptions, Chinese pharmaceutical imports, U.S. manufacturing capabilities, Contract development and manufacturing organizations (CDMOs), Pharmaceutical supply chain resilience
Frazier Replenishes Fund with $630 Million for Public Biotech Investments
Frazier, biotech fund, public biotechs, investment, biotechnology
Septerna Embarks on IPO Journey with Promising Preclinical Data and Vision to Revolutionize GPCR Drug Discovery
Septerna, IPO, GPCR, preclinical data, drug discovery, biotechnology, PTH1R agonists, hypoparathyroidism
Frazier Life Sciences Boosts Evergreen Fund with $630M for Small and Mid-Cap Biotechs
Frazier Life Sciences, Evergreen Fund, Small and Mid-Cap Biotechs, Healthcare Investment, Biotechnology Funding
IGM Biosciences Shifts Focus to Autoimmune Diseases Amid Leadership Changes
IGM Biosciences, autoimmune diseases, C-suite exits, biotechnology, immunology, arthritis, lupus
Amgen’s Mixed Results: A Tale of Two Readouts in Eczema and Myasthenia Gravis Trials
Amgen, Clinical Trials, Eczema, Myasthenia Gravis, Rocatinlimab, Uplizna, Biotechnology, Pharmaceutical Industry
Upstream Biotech Prepares to Join the Wave of Biotech IPOs with Inflammation-Focused Therapies
Biotech IPOs, Upstream Biotech, Inflammation-focused therapies, Biotechnology industry, Public offerings, Healthcare innovation